Establishing breast cancer chemoprevention in standard clinical practice requires advances in many different fields, including biomarker research, the development of more powerful tools to predict and communicate the risks and benefits of treatments and establishing innovative trial designs. In this Review, the authors examine the efforts in breast cancer chemoprevention and explain why the field is progressing slowly than hoped.
- Kathrin Strasser-Weippl
- Paul E. Goss
